Tovorafenib

Major

Tovorafenib Clindamycin ANTIROBE Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Colchicine Colcrys Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Abemaciclib Verzenio Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Acalabrutinib Calquence Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Atogepant Qulipta Reduced atogepant exposure Details Tovorafenib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Tovorafenib Amlodipine Amvaz® Reduced amLODIPine exposure Details Tovorafenib Axitinib Inlyta Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Bosutinib Bosulif Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Brigatinib Alunbrig Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Clindamycin Injection ANTIROBE Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Clindamycin Topical C/T/S® Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Clindamycin Vaginal Cleocin Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Clopidogrel Plavix Increased tovorafenib exposure and an increased risk of tovorafenib-related adverse effects Details Tovorafenib Cobimetinib Cotellic Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Cyclosporine Injection Atopica Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Cyclosporine Ophthalmic Cequa Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Dasatinib Phyrago Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Deferasirox Exjade Increased tovorafenib exposure and an increased risk of tovorafenib-related adverse effects Details Tovorafenib Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Dihydroergotamine Nasal Spray Migranal Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Docetaxel Beizray Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Docetaxel Injection Beizray Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Dofetilide Tikosyn Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Entrectinib Rozlytrek Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Estradiol Delestrogen Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Tovorafenib Estradiol Topical Divigel Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Tovorafenib Estradiol Transdermal Patch Alora® Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Tovorafenib Everolimus Afinitor Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Fentanyl Transdermal Patch Duragesic® Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Gemfibrozil Lopid Increased tovorafenib exposure and an increased risk of tovorafenib-related adverse effects Details Tovorafenib Letermovir Injection Prevymis Increased tovorafenib exposure and an increased risk of tovorafenib-related adverse effects Details Tovorafenib Levonorgestrel After banger Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Tovorafenib Levonorgestrel Intrauterine System Kyleena Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Tovorafenib Lumateperone Caplyta Reduced lumateperone exposure Details Tovorafenib Medroxyprogesterone Amen® Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Tovorafenib Medroxyprogesterone Injection Depo-Provera Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Tovorafenib Midostaurin Rydapt Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Neratinib Nerlynx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Tovorafenib Nifedipine Adalat® Reduced NIFEdipine exposure Details